title: Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
abstract: Several hemostatic and vascular endothelial cell markers were measured in 39 patients with thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) and in 20 healthy volunteers to examine the relationship between the occurrence of hemostatic abnormality or vascular endothelial cell injury and patient outcome. The plasma levels of von Willebrand factor, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI-1), and the TPA-PAI-1 complex were significantly increased in TTP/HUS patients; however, the levels of these markers were not significantly different between TTP/HUS patients who survived and those who died, suggesting that these markers might not be directly related to outcome. The plasma levels of soluble granule membrane protein (GMP)-140 were significantly higher in TTP/HUS patients than in healthy volunteers, suggesting that platelets and vascular endothelial cells are activated or injured in TTP/HUS. There was no significant difference in GMP-140 levels between TTP/HUS patients with good and poor prognoses; this may be owing to the release of GMP-140 from platelets. The plasma thrombomodulin (TM) levels in TTP/HUS patients were significantly higher than in healthy volunteers; the plasma TM levels were significantly higher in patients who died than in patients who survived. These findings showed that TM levels reflect the outcome and that the outcome of TTP/HUS depends on the presence vascular endothelial cell injury. The plasma protein C and antithrombin levels were markedly reduced in TTP/HUS patients who died compared with those who survived. These findings suggest that reduced plasma antithrombin and protein C may be useful markers of systemic vascular endothelial injury. In conclusion, the results of this study showed that the outcome of TTP/HUS is related to vascular endothelial cell injury and that plasma TM, antithrombin, and protein C levels may be useful markers of systemic vascular endothelial cell injury.
authors.affiliation: Mie Red Cross Blood Center, Mie University School of Medicine, Tsu-city, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Okugawa
authors.forename: S
authors.initials: S
authors.lastname: Tamaki
authors.forename: T
authors.initials: T
authors.lastname: Nakasaki
authors.forename: R
authors.initials: R
authors.lastname: Watanabe
authors.forename: E C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: M
authors.initials: M
authors.lastname: Nishikawa
authors.forename: N
authors.initials: N
authors.lastname: Minami
authors.forename: H
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology*; D006463:Hemolytic-Uremic Syndrome / Q000097:blood* / Q000209:etiology / Q000401:mortality; D006490:Hemostatics / Q000097:blood; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood* / Q000401:mortality; D015996:Survival Rate; D018180:Thrombomodulin / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006490:Hemostatics; D018180:Thrombomodulin